Summary
L-LPHARMA is a financial institution; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €593,621 and a net result of €128,582. Equity is growing by about 21% per year across the filed financial years. Its solvency ranks better than 45% of 9,732 sector peers (NACE 64, financial year 2025). The company has been active since 2016 and the Belgian Official Gazette contains no insolvency or warning signals.
Articles of association
- Transfer restrictionWhether shareholders may sell their shares freely or need approval first.
- “Helft overdrager,helft koper(s) naar evenredigheid aantal aandelen, vermelde prijs of deskundige bij betwisting” (deed in Dutch)
Read from the deeds: 1 provision, deed of 14-12-2023